6533b862fe1ef96bd12c62c8

RESEARCH PRODUCT

Reduced firing rates of pyramidal cells in the frontal cortex of APP/PS1 can be restored by acute treatment with levetiracetam

Jan L. KleeArto LipponenAmanda J. KiliaanFrancesco P. Battaglia

subject

Male0301 basic medicineAgingAlzheimer`s disease Donders Center for Medical Neuroscience [Radboudumc 1]LevetiracetamAction PotentialsamyloidoosiLocal field potentialAlzheimerin tautiAmyloid beta-Protein Precursor0302 clinical medicineBeta RhythmChemistryPyramidal CellsGeneral Neuroscienceamyloidfood and beveragesAmyloidosisPhenotypePathophysiologyFrontal Lobesingle cellmedicine.anatomical_structureLevetiracetamPyramidal cellAlzheimer’s diseasemedicine.drugNeuroinformaticspatofysiologiaAmyloidmouse modelTransgeneMice Transgenic03 medical and health sciencesAlzheimer Diseasemental disordersPresenilin-1medicineAnimalslocal field potential (LFP)hermosolutDisease Models Animal030104 developmental biologynervous systemfiring rateNeurology (clinical)Geriatrics and GerontologyNeuroscience030217 neurology & neurosurgeryDevelopmental Biology

description

Contains fulltext : 229488.pdf (Publisher’s version ) (Open Access) Contains fulltext : 229488pre.pdf (Author’s version preprint ) (Open Access) In recent years, aberrant neural oscillations in various cortical areas have emerged as a common physiological hallmark across mouse models of amyloid pathology and patients with Alzheimer's disease. However, much less is known about the underlying effect of amyloid pathology on single cell activity. Here, we used high-density silicon probe recordings from frontal cortex area of 9-month-old APP/PS1 mice to show that local field potential power in the theta and beta band is increased in transgenic animals, whereas single-cell firing rates, specifically of putative pyramidal cells, are significantly reduced. At the same time, these sparsely firing pyramidal cells phase-lock their spiking activity more strongly to the ongoing theta and beta rhythms. Furthermore, we demonstrated that the antiepileptic drug, levetiracetam, counteracts these effects by increasing pyramidal cell firing rates in APP/PS1 mice and uncoupling pyramidal cells and interneurons. Overall, our results highlight reduced firing rates of cortical pyramidal cells as a pathophysiological phenotype in APP/PS1 mice and indicate a potentially beneficial effect of acute levetiracetam treatment.

https://doi.org/10.1016/j.neurobiolaging.2020.08.013